Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million Funding award milestone follows Daré's announcement last week of t
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. gover
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
09:40pm, Thursday, 14'th May 2026
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 14'th May 2026
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summe
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?
02:21pm, Tuesday, 12'th May 2026
Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is reporting positive interim results from its Phase 3 clinical trial for Ovaprene, a hormone-free contracept
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
08:00am, Tuesday, 12'th May 2026
Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DI
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
08:00am, Thursday, 07'th May 2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising scienc
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
06:56pm, Thursday, 26'th Mar 2026
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
06:21pm, Thursday, 26'th Mar 2026
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.64 per share a year ago.
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 26'th Mar 2026
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts
On National Viagra Day, Women Finally Claim Their Turn:
08:00am, Monday, 23'rd Mar 2026
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
08:00am, Thursday, 12'th Mar 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women's health
DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies DARE-HPV development supported by $10 million ARPA-H contract; program ta
Dare Bioscience (NASDAQ:DARE) Stock Crosses Below 200 Day Moving Average – Time to Sell?
03:10am, Saturday, 24'th Jan 2026
Dare Bioscience, Inc. (NASDAQ: DARE - Get Free Report) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $2.10 and traded as l
